

**CENTER FOR DRUG EVALUATION AND
RESEARCH**

APPLICATION NUMBER:

21-014/S-003

APPROVAL LETTER



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville, MD 20857

NDA 21-014/S-003

Novartis Pharmaceuticals Corporation
Attention: Mara Stiles
Associate Director, Drug Regulatory Affairs
59 Route 10
East Hanover, New Jersey 07936-1080

Dear Ms. Stiles:

Please refer to your supplemental new drug application dated February 9, 2001, received February 12, 2001, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Trileptal® (oxcarbazepine) Tablets.

We acknowledge receipt of your submission dated July 23, 2003.

The February 6, 2003 submission constituted a complete response to our December 12, 2001 action letter.

This new drug application provides for the use of Trileptal as monotherapy in the treatment of partial seizures in children ages 4-16.

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the attached agreed-upon labeling text.

In addition, submit three copies of the introductory promotional materials that you propose to use for this product. Submit all proposed materials in draft or mock-up form, not final print. Send one copy to this Division and two copies of both the promotional materials and the package insert directly to:

Division of Drug Marketing, Advertising,
and Communications, HFD-42
Food and Drug Administration
5600 Fishers Lane
Rockville, MD 20857

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

The MedWatch-to-Manufacturer Program provides manufacturers with copies of serious adverse event reports that are received directly by the FDA. New molecular entities and important new biologics qualify for inclusion for three years after approval. Your firm is eligible to receive copies of reports for

this product. To participate in the program, please see the enrollment instructions and program description details at www.fda.gov/medwatch/report/mmp.htm.

If you have any questions, call Melina Griffis, R. Ph., Regulatory Project Manager, at (301) 594-5526.

Sincerely,

{See appended electronic signature page}

Russell Katz, M.D.

Director

Division of Neuropharmacological Drug Products

Office of Drug Evaluation I

Center for Drug Evaluation and Research

APPROVED FOR
ORIGINAL

**This is a representation of an electronic record that was signed electronically and
this page is the manifestation of the electronic signature.**

/s/

Russell Katz

8/7/03 01:32:30 PM

ALL INFORMATION CONTAINED
HEREIN IS UNCLASSIFIED
DATE 08-07-03 BY 60322